Navigation Links
Old drug holds promise against opportunistic lung bug
Date:8/19/2010

more than 80 percent of children have been infected by the age of 2. Most people shake off the infection without consequence, but for people with cancer, AIDS, or other diseases that compromise their immune system, the infection can be deadly. Usually there are few signs that the patient is sick until the infection is well established and the fungus is widespread in the lungs. Among cancer patients, mortality rates as high as 40 percent have been reported.

Since the body's immune response is central to how Pneumocystis kills patients, doctors use two different types of drugs in tandem to treat patients an antibiotic to kill the bug, and steroids or another type of drug to reduce the consequent inflammation.

Central to the study were mice in which the disease progresses in a manner very similar to AIDS patients. The remarkable strides in AIDS therapy in recent years have come with a down side for many patients, thanks to Pneumocystis: When anti-retroviral therapy kicks in, a patient's immune system often becomes stronger very quickly and if the fungus is present, the immune system attacks it vigorously, causing a potentially deadly form of pneumonia.

Wright's team looked at the effects in mice of sulfasalazine, an anti-inflammatory drug that has proven useful in treating conditions like Crohn's disease and rheumatoid arthritis. The team found that Pneumocystis-infected mice treated with sulfasalazine developed much less severe disease than untreated mice. The sulfasalazine-treated mice had better lung function, less weight loss, and were generally healthier than untreated animals.

While some of the benefit was due to the drug's anti-inflammatory properties and was expected, the result included a big surprise: The drug also spurs the body to remove the bug more aggressively by boosting the activity of immune cells called macrophages.

"This was unexpected," said first author Jing Wang, Ph.D., research
'/>"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. AthletiCo Physical Therapy Holds July Cell Phone Drive
2. Chinese Biopharmaceutical Association Successfully Holds 15th Annual Conference
3. U.S. Panel Upholds Ban on Gay Men as Blood Donors
4. SISEL International Holds Successful Launch Events In Ukraine
5. Baden Elementary School holds VisionWalk to Fight Blindness
6. ShenoaDiamonds.com Holds Contest to Give Away $5,000 Diamond Ring, Spurred by Online Sales Growth
7. Construction Accident Lawyer Says Recent News Of Mine Disaster Holds Lessons For Construction Safety
8. ATSU –ASHS Holds Spring Commencement Ceremony
9. Morehead Associates, Inc. Holds Annual Peer to Peer Conference(TM)
10. Gene Holds Key to Embryonic Stem Cell Rejuvenation
11. Ongoing Toyota Recall Holds Serious Liability Implications For Manufacturer, but Consumers Must Be Protected, Says Texas Attorney Brad T. Wyly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... MADISON, Wis., and BIRMINGHAM, Ala., Sept. 14 ... is now offering a specialized,professional liability program ... being made available through Physicians Insurance Company,of ... "We are pleased to have the ...
... (HealthDay News) -- It,s under your movie seat and glued ... relief may be in sight. This week, researchers say they,ll ... at the BA Festival of Science in York, England. , ... and sidewalks, and preliminary tests indicate that it degrades naturally ...
... STAUNTON, Va., Sept. 14 Michael Bond has,been ... joins,the company following nearly 30 years in various ... Director of Blade Process,Engineering. Bond has a wealth ... advancement of leading edge technologies for,IncisionTech and Specialty ...
... Sept. 14 Stryker,Corporation (NYSE: SYK ) announced ... September 25, 2007 - 4:30 p.m. Eastern Time ... New York A simultaneous webcast of the Company,s ... via the For Investors page. The,presentation for the ...
... Sept. 14 Most people looking for tax advice,usually ... usually see,mechanics, right? Here,s more on a new report ... and questions are actually not seeing the pros,trained in ... at:, http://media.medialink.com/WebNR.aspx?story=33829 Registered journalists can access video, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced ... of Senior Vice President and Chief Compliance Officer. ... where she was,Director of Compliance for Latin America, ... for all compliance-related matters in those,regions. Prior to ...
Cached Medicine News:Health News:ProAssurance Group Offers Coverage for Community Based Hospitals in Michigan 2Health News:Specialty Blades, Inc. Expands Management Team With New VP Engineering 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... , , ... Orphan Drug Designation , SILVER SPRING, Md., Dec. 23 ... more transparent and accessible, the FDA has scheduled a series of ... unfamiliar with the process. The FDA can grant a special status, ...
... , , PHILADELPHIA, Dec. 23 URL Pharma today announced ... initiative designed to save patients money on their health insurance co-payment ... no more than $25 for a Colcrys prescription, which equates to ... the prevention and treatment of gout flares and for the treatment ...
Cached Medicine Technology:FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 2URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 3URL Pharma Launches Co-Pay Assistance Program for Colcrys(R) 4
...
... System is a complete anterior ... portable, it offers high-end performance ... console. It also provides all ... segment surgery. These include Irrigation, ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: